Sclerosis
9
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Aerobic Exercise for Remyelination in Multiple Sclerosis
Effects of Individualized Training to Reduce Fatigue in Patients With Newly and Advanced Diagnosed Multiple Sclerosis
Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis
Power Training in Older Multiple Sclerosis Patients
Scleroderma: Cyclophosphamide or Transplantation
Assessment of Language Disorders in Multiple Sclerosis Patients
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)